Clinical Trial Update: A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL) [Phase 3]

View source ↗

Summary

A Phase 3 open-label trial evaluating two ABC/3TC-based regimens in late presenters with HIV infection who are treatment-naïve and have CD4 counts below 200 cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• ABC/3TC (abacavir/lamivudine)
• ABC/3TC based regimens (abacavir/lamivudine-based regimens)

Snippet

Sponsor: University of Modena and Reggio Emilia | Conditions: HIV Infection | Phase 3 | Status: COMPLETED